Business

Know the Business

Bottom line. Garware Hi-Tech Films is not a commodity polyester films company — that was its past. Today it is a specialty consumer-facing brand (Sun Control Films, Paint Protection Films) that happens to be vertically integrated back to polyester chips, and this mix-shift is why ROCE jumped from high-single-digits in FY16–18 to 21% in FY25 while every BOPET peer is still struggling. The market is probably underestimating how much of the margin structure now depends on US PPF pricing power — and overestimating how much a manufacturing peer like Jindal Poly or Polyplex can replicate the brand + distribution moat that took Garware 15 years to build.

1. How This Business Actually Works

The economic engine is simple to describe and hard to copy: buy PTA + MEG, polymerize into PET chips, extrude into BOPET base film, then coat, tint, metallize and laminate that film into Sun Control Film (blocks heat through glass), Paint Protection Film (urethane-top-coated film that shields car paint) and industrial niches (shrink sleeves, release liners). The more coating, converting, branding and distribution you layer on top of the same base film, the more the revenue per square foot multiplies — and the less it correlates with crude-oil-driven PET chip spreads.

Every incremental rupee of EBITDA for the next five years almost certainly comes from four levers, in order of magnitude: (1) PPF capacity ramp — the company doubled capacity to 600 LSF p.a. in Sep 2025, current new-line utilization ~65%, adds a TPU backward-integration line Oct 2026 for another 360 LSF; (2) architectural SCF — now 22–23% of Consumer Products revenue (~₹300 Cr), guided to ₹500 Cr by FY28 via Middle East + Home Solutions D2C; (3) geographic rebalancing away from concentrated US exposure (US was 43% of revenue pre-tariff, 40% in Q3 FY26, Middle East 4% → 8% in a year); (4) price/mix discipline — the Q3 FY26 result showed they can absorb a 50% US tariff and keep EBITDA margin at 18.9% by raising mix toward IR-blocking premium SCF and PPF.

The real bottleneck is not manufacturing; capacity expansions here are 18-month exercises of ~₹100–150 Cr each. The bottleneck is applicator and distribution build-out — the 250+ Garware Application Studios (company-branded PPF install bays), the 1,000+ trained applicators, the 300+ target by FY26. This is why operating leverage will not arrive as a single step-up: each new studio, each new dealer contract in Italy or Dubai, each Bajaj Finance EMI tie-up in Mumbai is a slow compound, and that is exactly the kind of moat that doesn't show up on a DCF until it already has.

Cost structure is RM-heavy (polyester chips + PTA/MEG, imported coatings and urethane top-coats, specialty additives), so gross margins swing with crude. But because SCF/PPF unit prices are 4–10x the underlying chip value, a 20% jump in chip prices compresses CPD EBITDA margin by only 150–200 bps — in the IPD half of the book that same input shock would halve margins. That insulation is the entire reason consolidated operating margins held 17–21% through FY22–25 while Polyplex, UFlex and Cosmo First all gave back 6–10 points.

2. The Playing Field

The cleanest way to see Garware's position is to plot profitability against scale — the Indian polyester/polymer films universe has two giants (SRF, UFlex) that are diversified far beyond films, one mid-cap (Jindal Poly) that is pure BOPET/BOPP, and a cluster of mid-caps below ₹10,000 Cr. Garware is the only one that has escaped commodity returns.

The peer table reveals three things that the sell-side consensus understates. First, the ROCE gap is structural, not cyclical: Jindal Poly (India's largest BOPET maker), Polyplex (globally diversified) and Ester (old-line polyester) all earn mid-single-digit returns in good years and negative returns in bad ones, because their book is 80%+ commodity BOPET/BOPP/shrink. Garware earns 21% ROCE because 87% of its revenue is value-added and 71% is consumer. Second, the only other peer with a real consumer franchise is Cosmo First (Zigly pet care, Cosmo Specialty Chemicals), but its films business is BOPP packaging, not specialty window films — there is no direct SCF/PPF competitor at Garware's price point in India. Third, SRF is often quoted as a peer but its films segment is commodity BOPP/BOPET; the premium valuation is earned by its fluorine-chemicals franchise, not films. The right way to think about Garware is as a consumer-specialty compounder that accidentally lives inside a BOPET cost base, surrounded by pure commodity peers.

3. Is This Business Cyclical?

Yes, but the cycle has moved. The historical cycle was chip spreads (PTA/MEG vs PET chip price) driving a textbook boom–bust every 4–6 years: FY21–22 delivered the biggest BOPET margin expansion in a decade (Polyplex OPM 25%, Jindal Poly 27%), followed by a brutal normalization through FY23–24 where every commodity peer gave back 10–15 margin points. Garware's current cycle exposure is different because of the consumer mix — the cycle now hits (in order of force) US tariff/demand, coatings/urethane input costs, and only last the underlying BOPET spread.

The real cyclical risk today is US demand. The Q3 FY26 transcript confirms US tariffs stepped from 25% to 50% during the quarter, and ~40% of Q3 revenue went to the US. Management absorbed ~₹40 Cr of the expected ~₹50 Cr tariff hit through product-mix shift (higher IR-blocking SCF, premium PPF), limited pass-through to distributors, and re-routing of bonded-warehouse inventory. The buffer works because PPF carries gross margins high enough to absorb a 25-point tariff hike without volume destruction — try that on plain BOPET shrink film and the entire margin disappears. Working capital matters here: inventory days jumped from 109 in FY23 to 132 in FY24 back to 116 in FY25 and management says US bonded-warehouse inventory is currently at ~100 days vs a normal 60–75, holding back invoiced sales in hopes of a tariff rollback.

4. The Metrics That Actually Matter

Forget consolidated revenue growth — it averages both divisions and hides the story. The scorecard below lists the numbers that actually explain value creation here; the top three (VAP share, Consumer Division share, PPF utilization) do the heaviest lifting:

Why these beat the usual ratios: revenue growth in a two-division business is almost meaningless (the IPD half can grow 15% on a BOPET spread bounce while CPD is flat, and investors should care about the opposite). Value-added product share is the one metric that has moved in a straight line for eight years (28% → 87%) and is the single best explanation for why ROCE tripled. US/non-US revenue split matters more than total revenue because of tariff risk — Middle East already doubled to 8% of revenue in one year and Europe is stable at ~11%, so the denominator of "tariff-exposed US" should shrink. PPF utilization on the new line is the measurable form of the FY27 earnings lever (doubling capacity from 300 LSF to 600 LSF at ~25% higher ASPs than SCF). GAS studio count + applicator training volume is the slow-compound distribution moat — it's what makes the business defensible when Chinese economy-tier films try to enter via price.

Crucially, the Indian reporting convention hides a powerful operating leverage: depreciation is only ~₹40–45 Cr per year on ₹14,500 Cr of gross block because much of the plant is old and fully depreciated, so every incremental rupee of gross profit drops almost unimpeded to PBT. This is why PAT CAGR (FY21–25: 27%) has run ahead of revenue CAGR (21%) — but it also means the next major capex cycle (TPU line + potential UAE manufacturing) will eventually drag D&A up and partially compress this tailwind.

5. What I'd Tell a Young Analyst

Watch the mix, not the headline. A 10% consolidated revenue decline in a quarter where CPD grows 15% and IPD falls 25% is a bullish print — and the company reports both divisions cleanly. If CPD revenue ever decelerates below 15% YoY growth for two consecutive quarters without a clear tariff explanation, the thesis has a problem.

The US tariff is not the risk the market thinks it is. Garware has already shown it can hold 18–20% EBITDA margin under a 50% tariff by re-routing sales to Middle East, Europe and non-tariff geographies. The real risk is a sustained 3–4 quarter demand shock in the US auto-aftermarket, which would idle the new 600 LSF PPF line and delay the ramp that is the biggest earnings lever for FY27–28.

Don't confuse this with a BOPET pair-trade. Every time Polyplex or Jindal Poly trades cheap and someone frames Garware against it, remember: the FY24 margin collapse hit pure BOPET peers 10–15 points and Garware 2 points, and the FY21 BOPET spike lifted peer peers 10 points and Garware 5. The specialty mix has permanently broken the correlation — Garware's cycle is now paint, cars, construction glazing and consumer PPF, not PET chip spreads.

The thesis changes if any of four things happen. (1) US imposes a tariff specifically on PPF/SCF higher than 50% with no Middle East re-route path; (2) the TPU line fails to commission on time in Oct 2026 and PPF capacity stays backward-integration-limited; (3) a Chinese or Korean premium brand lands a global distribution partnership (3M, Eastman) that breaches the top-end price umbrella; (4) management pulls an M&A distraction outside films — the cash balance (₹669 Cr) is the most visible form of risk on this front.

What the market is probably missing. The FII shareholding went from 0.3% to 3.96% between Mar-24 and Dec-25 — a 13x jump in 21 months. Promoters sit at 60.7% and haven't diluted. Retail is 30%. This is still an under-owned midcap where the institutional base is just forming — if CPD delivers another 15–20% growth year in FY27 and the tariff narrative eases, the re-rating leg is available simply because the float needs to be absorbed by larger funds. That's not a thesis on its own, but it's the setup that makes a thesis-driven entry rewarding.